Table 1.

Clinical characterization of patients with SCD used in the PLA assay

Female/male 6/4 
Age (y) 41.40 (41; 30-61) 
Red blood cells (×103/μL) 2.82 (2.55; 1.92-4.8) 
Hemoglobin (g/dL) 9.52 (9.65; 6.8-13.7) 
Hematocrit (%) 27.37 (28.55; 19.6-37.7) 
White blood cells (×103/μL) 8.69 (7.35; 3.2-13.2) 
% neutrophils 56.38 (58.3; 39-72) 
% lymphocytes 26.09 (21.75; 8-49) 
% monocytes 8.9 (9.45; 1.4-14) 
Platelets (×103/μL) 360.2 (308.5; 113-860) 
% HbF 13.51 (9.75; 1.5-35.4) 
SCD genotype  
SS 
S/β0 
SC 
Hydroxyurea (yes/no) 6/4 
Female/male 6/4 
Age (y) 41.40 (41; 30-61) 
Red blood cells (×103/μL) 2.82 (2.55; 1.92-4.8) 
Hemoglobin (g/dL) 9.52 (9.65; 6.8-13.7) 
Hematocrit (%) 27.37 (28.55; 19.6-37.7) 
White blood cells (×103/μL) 8.69 (7.35; 3.2-13.2) 
% neutrophils 56.38 (58.3; 39-72) 
% lymphocytes 26.09 (21.75; 8-49) 
% monocytes 8.9 (9.45; 1.4-14) 
Platelets (×103/μL) 360.2 (308.5; 113-860) 
% HbF 13.51 (9.75; 1.5-35.4) 
SCD genotype  
SS 
S/β0 
SC 
Hydroxyurea (yes/no) 6/4 

Data show mean (median; range) except for the sex and hydroxyurea status.

HbF, fetal hemoglobin; S/β0, sickle β0-thalassemia; SC, hemoglobin SC disease; SS, sickle cell anemia.

or Create an Account

Close Modal
Close Modal